ArticleCurrent genomics2023
Pan-cancer Analysis Identifies AIMP2 as a Potential Biomarker for Breast Cancer.
Article in Current genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 26 citations in OpenAlex.
- DNMT1 promotes the malignant progression of colorectal cancer by silencing HOXD11 via promoter hypermethylation.Discover oncology · 2026Article
- Multi-cohort and single-cell profiling of aging genes reveals prognostic and therapeutic targets in breast cancer.iScience · 2026Article
- Single-cell transcriptomics uncover RNF130-mediated TNF-α pathway activation and worenine synergy with paclitaxel in breast cancer.Clinical epigenetics · 2026Article
- Downregulation of USP39 in sepsis reflects immune dysfunction and offers diagnostic and prognostic value.European journal of medical research · 2026Article
- Establishment of Centrosome Amplification-Correlated Model to Evaluate the Tumor Immune Microenvironment and Prognosis of Patients with Glioblastoma.Current medicinal chemistry · 2026Article
- Article
- Construction and validation of a lung adenocarcinoma prognostic model based on neutrophil extracellular traps and oxidative stress-related genes.European journal of medical research · 2025Article
- Pan-cancer analysis of DTX3L as a potential prognostic and immunological biomarker.Scientific reports · 2025Article
- Guanylate-binding proteins score and a CBFA2T3-included risk model define immune microenvironment and chemosensitivity in lung adenocarcinoma.European journal of medical research · 2025Article
- CCL8 suppresses ovarian cancer progression via M1 macrophage polarization and NF-κB-mediated apoptosis.Scientific reports · 2025Article
- CEACAM6 regulates glycolytic metabolism in bladder cancer cell by controlling ENO1 stability.European journal of medical research · 2025Article
- E2F transcription factors as multimodal biomarkers for pan-cancer management.Scientific reports · 2025Article
- Dual targeting of PD-1/PD-L1 and iL-33/ST2 signalling pathways: a promising approach in breast cancer immunotherapy.Annals of medicine · 2025Review
- A fibroblast-specific gene signature as a therapeutic target for glioblastoma developed based on the characteristics of tumor microenvironment.European journal of medical research · 2025Article
- Single cell and machine learning identify type II pneumocyte-derived biomarkers HN1/OCIAD2/SFTA2 for non-small cell lung cancer prognosis and immune regulation.European journal of medical research · 2025Article
- A pan-cancer analysis of CTSC as a candidate prognostic and immune-related biomarker.Discover oncology · 2025Article
- Integrating machine learning and experimental validation identifies a post-translational modification gene signature for prognosis and treatment response in breast cancer.Scientific reports · 2025Article
- Single-cell RNA sequencing and in vitro validation reveal risankizumab induces anti-inflammatory macrophage polarization in psoriasis.European journal of medical research · 2025Article
- Comprehensive pan-cancer analysis of KRT6A as a prognostic and immune biomarker.Scientific reports · 2025Article
- Suppression of STK11 induces expansion of polymorphonuclear myeloid-derived suppressive cells and activation of immune signaling in breast cancer.Cancer immunology, immunotherapy : CII · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Aminoacyl tRNA synthetase complex interacting with multifunctional protein 2 (AIMP2) is a significant regulator of cell proliferation and apoptosis. Despite its abnormal expression in various tumor types, the specific functions and effects of AIMP2 on tumor immune cell infiltration, proliferation, and migration remain unclear. Materials and Methods: To assess AIMP2's role in tumor immunity, we conducted a pan-cancer multi-database analysis using the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and Cancer Cell Lines Encyclopedia (CCLE) datasets, examining expression levels, prognosis, tumor progression, and immune microenvironment. Additionally, we investigated AIMP2's impact on breast cancer (BRCA) proliferation and migration using cell counting kit 8 (CCK-8) assay, transwell assays, and western blot analysis. Results: Our findings revealed that AIMP2 was overexpressed in 24 tumor tissue types compared to normal tissue and was associated with four tumor stages. Survival analysis indicated that AIMP2 expression was strongly correlated with overall survival (OS) in certain cancer patients, with high AIMP2 expression linked to poorer prognosis in five cancer types. Conclusion: Finally, siRNA-mediated AIMP2 knockdown inhibited BRCA cell proliferation and migration
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.